Pulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of “Moderate Buy” by Brokerages

Pulmonx Co. (NASDAQ:LUNG) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.07.

Several analysts have recently issued reports on LUNG shares. D. Boral Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Pulmonx in a research note on Thursday, May 1st. Jefferies Financial Group started coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating on the stock. Piper Sandler reissued an “overweight” rating and issued a $9.00 target price (down previously from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Morgan Stanley started coverage on Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating on the stock. Finally, Citigroup started coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating on the stock.

Insiders Place Their Bets

In other Pulmonx news, CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.14, for a total transaction of $197,699.46. Following the transaction, the chief executive officer now owns 194,342 shares of the company’s stock, valued at approximately $1,387,601.88. This trade represents a 12.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel David Aaron Lehman sold 22,355 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.65, for a total value of $171,015.75. Following the transaction, the general counsel now directly owns 175,496 shares in the company, valued at approximately $1,342,544.40. The trade was a 11.30% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 145,660 shares of company stock valued at $1,128,484. 6.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pulmonx

Several hedge funds have recently made changes to their positions in LUNG. BNP Paribas Financial Markets purchased a new position in shares of Pulmonx during the fourth quarter worth about $43,000. R Squared Ltd purchased a new position in shares of Pulmonx during the fourth quarter worth about $46,000. ProShare Advisors LLC purchased a new position in shares of Pulmonx during the fourth quarter worth about $72,000. Stifel Financial Corp purchased a new position in shares of Pulmonx during the fourth quarter worth about $81,000. Finally, Vontobel Holding Ltd. purchased a new position in shares of Pulmonx during the first quarter worth about $82,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Up 0.3%

Shares of NASDAQ LUNG opened at $3.43 on Friday. The stock has a market cap of $138.08 million, a P/E ratio of -2.38 and a beta of 0.65. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx has a 12-month low of $3.18 and a 12-month high of $9.37. The business’s fifty day simple moving average is $5.50 and its 200-day simple moving average is $6.33.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.01. The business had revenue of $22.54 million for the quarter, compared to analysts’ expectations of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, equities analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.